The 2-Minute Rule for ABBV-744 in the treatment of drug-resistant cancers
In Segment C, individuals will acquire ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Participants will obtain treatment until disorder progression or the individuals are not able to tolerate the study drugs.Ubiquitin-related proteins that regulate The soundness of key super enhancer-mediated proteins hav